Skip to main content
OpenTrials

Clinical trial condition

Varicella Zoster Virus Infection

Explore clinical trials studying Varicella Zoster Virus Infection. Study availability and eligibility vary by location and protocol.

341 public trials 40 recruiting studies
Refine in advanced search Browse all conditions

Varicella Zoster Virus Infection trial results

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

NCT01827839

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Coquitlam, British Columbia, Canada
  • GSK Investigational Site Pointe-Claire, Quebec, Canada
  • GSK Investigational Site Barnaul, Russia
  • GSK Investigational Site Yekaterinburg, Russia
View Trial Details
Completed

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

NCT01751165

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Spring Valley, California, United States
  • GSK Investigational Site Wichita, Kansas, United States
  • GSK Investigational Site Uniontown, Pennsylvania, United States
  • GSK Investigational Site Tartu, Estonia
View Trial Details
Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

NCT00578175

Conditions
Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Tuscaloosa, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
View all 141 locations
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

NCT02581410

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Los Gatos, California, United States
  • GSK Investigational Site Oakland, California, United States
View all 32 locations
View Trial Details
Completed

Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

NCT01506193

Conditions
Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations
  • GSK Investigational Site Rome, Lazio, Italy
  • GSK Investigational Site Chiavari, Liguria, Italy
  • GSK Investigational Site Genoa, Liguria, Italy
  • GSK Investigational Site Milan, Lombardy, Italy
View all 13 locations
View Trial Details

Related conditions